Abstract: Background The purpose of PsABio (ClinicalTrials.gov Id: NCT02627768) is to evaluate the efficacy, tolerability and persistence of TNF inhibitors (TNFi) and ustekinumab (UST) for patients with psoriatic arthritis (PsA) starting 1st, 2nd or 3rd line biologic disease-modifying antirheumatic drugs (bDMARDs) in real-world routine care. Objectives Here we present the first interim follow-up data on joint-related outcomes. Methods Of 278 UST- and 285 TNFi-treated patients consecutively enrolled between Dec 2015 and ,Aug 2017 152 and 151, respectively...
(read more)
Topics: 
Dermatology
Immunology
Internal medicine